383 articles with Bayer AG
AskBio Co-Founder Jude Samulski Receives Inaugural European Society of Gene and Cell Therapy Founders Award
Asklepios BioPharmaceutical, Inc. announced that R. Jude Samulski, Ph.D., AskBio President, Co-Founder and Chief Scientific Officer, received the inaugural European Society of Gene and Cell Therapy Founders Award in Edinburgh, Scotland, during the recent ESGCT 29th Congress.
Innovative business model preserves Vividion’s entrepreneurial culture and pipeline focus, while adding the technical expertise and resources of a global pharma leader.
AskBio President of Therapeutics Dr. Katherine High receives Award from American Society of Gene and Cell Therapy
Asklepios BioPharmaceutical, Inc., a wholly owned and independently operated subsidiary of Bayer AG, announced that Dr. Katherine High, President of Therapeutics, received the Jerry Mendell award for Translational Science from the American Society of Gene and Cell Therapy.
Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
Organon announced that it has acquired the rights from Bayer AG to Marvelon® and Mercilon®, combined oral hormonal daily contraceptive pills, in the People’s Republic of China, including Hong Kong and Macau, and has entered into an agreement to acquire the rights to these products in Vietnam.
Asklepios BioPharmaceutical, Inc., a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, and Touchlight, a biotechnology company pioneering enzymatic DNA production, have announced a revised structure to their former joint venture, Touchlight AAV.
Leaps by Bayer Leads $80M Series A Financing for Cellino Biotech to Autonomize Stem Cell Therapy Manufacturing
Cellino Biotech, Inc., an autonomous cell therapy manufacturing company, today announced the completion of a Series A financing of $80 million, led by the impact investment arm of Bayer AG —Leaps by Bayer— 8VC, and Humboldt Fund.
Cellino is a closed loop cell therapy manufacturing company that aims to make stem cell-based regenerative therapies available to all eligible patients and researchers using cells in clinical research.
Celmatix Inc., a biotechnology company focused on ovarian biology, announced that a third milestone has been achieved in its five-year, multi-target alliance with Evotec.
Bayer AG and Mammoth Biosciences, Inc., which is harnessing the diversity of nature to power the next-generation CRISPR products, announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.
The cash came rolling in for four biopharma companies Thursday morning, with collective Series A rounds totaling more than $125 million.
Effective January 1, 2022: Rodrigo Santos Named Member of the Board of Management, Bayer AG, and President of the Crop Science Division
The Supervisory Board of Bayer AG has appointed Rodrigo Santos to the company’s Board of Management and the position of President of the Crop Science division, effective January 1, 2022.
Redosing is a large and growing concern for gene therapy developers and regulators.
Biomolecular condensates could hold the key to unlocking a number of neurological diseases that have baffled researchers the longest.
BWX Technologies, Inc. announced that its BWXT Medical Ltd. subsidiary has entered into an agreement with Bayer AG to develop Actinium-225 supply and further partnering opportunities on finished products as both companies broaden their respective commercialization strategies for targeted radionuclide therapies and other innovative products.
Versant Ventures announced that portfolio company Vividion Therapeutics has been acquired by Bayer AG for $1.5 billion up front and up to $500 million in potential future milestone payments.
Acquisition strengthens Bayer’s drug discovery capabilities with cutting-edge chemoproteomics platform
Under the terms of the agreement, Bayer is paying $1.5 billion upfront and up to $500 million in various milestone payments.
Bayer to Advance Two First-of-its-Kind Investigational Cell and Gene Therapies for Parkinson’s Disease
Bayer is pursuing a two-pronged approach to deliver transformative therapies with one cell and one gene therapy candidate in clinical trials.
Senti Bio and BlueRock Therapeutics Enter Collaboration to Develop Gene Circuit-Engineered Cell Therapies for Regenerative Medicine
Collaboration combines BlueRock’s leading induced pluripotent stem cell (iPSC) platform technology and genome biology expertise with Senti Bio’s proprietary gene circuit technology platform, including Smart Sensors and Regulator Dials
BioSpace takes an in-depth look at the Top 25 of Q1. You should be aware of these biopharma companies as they hold a great future ahead. So, check them out.